Is CBIO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CBIO. It does not provide personalized investment advice.

CBIO (Crescent Biopharma, Inc. Common Stock) Stock Analysis - Financials

Crescent Biopharma, Inc. Common Stock (CBIO) is a publicly traded Healthcare sector company. As of July 15, 2026, CBIO trades at $14.90 with a market cap of $432.65M and a P/E ratio of -193.44. CBIO moved -2.29% today. Year to date, CBIO is +29.05%; over the trailing twelve months it is +19.57%. Its 52-week range spans $8.72 to $27.41. Analyst consensus is strong buy with an average price target of $31.00. Rallies surfaces CBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are CBIO's key financials?

CBIO financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CBIO recently traded at $14.90. Market cap is $432.65M. P/E ratio is -193.44. Revenue is $117.05M.

CBIO Key Metrics

Key financial metrics for CBIO
Metric	Value
Price	$14.90
Market Cap	$432.65M
P/E Ratio	-193.44
EPS	$-0.08
Dividend Yield	0.00%
52-Week High	$27.41
52-Week Low	$8.72
Volume	53.47K
Avg Volume	0
Revenue (TTM)	$117.05M
Net Income	$-1.39M
Gross Margin	95.09%

CBIO Analyst Consensus

7 analysts cover CBIO: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $31.00.

Common questions about CBIO

What are CBIO's key financials?: CBIO financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CBIO recently traded at $14.90. Market cap is $432.65M. P/E ratio is -193.44. Revenue is $117.05M.
Is CBIO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CBIO. It does not provide personalized investment advice.